PMID- 33263178
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20211204
IS  - 2523-899X (Electronic)
IS  - 2523-899X (Linking)
VI  - 40
IP  - 6
DP  - 2020 Dec
TI  - Protective Effect of Irbesartan by Inhibiting ANGPTL2 Expression in Diabetic 
      Kidney Disease.
PG  - 1114-1120
LID - 10.1007/s11596-020-2304-z [doi]
AB  - Angiopoietin-like protein 2 (ANGPTL2) stimulates inflammation and is important in 
      the pathogenesis of diabetic kidney disease (DKD). Irbesartan is helpful in 
      reducing diabetes-induced renal damage. In this study, the effects of irbesartan 
      on DKD and its renal protective role involving ANGPTL2 in DKD rats were examined. 
      Wistar rats were divided into normal, DKD, and DKD + irbesartan groups. The DKD + 
      irbesartan group was treated once daily for 8 weeks with 50 mg/kg irbesartan via 
      intragastric gavage. The 24-h urinary albumin was determined each week, renal 
      pathological changes were observed, and expression of ANGPTL2 and nuclear 
      factor-kappa B (NF-kappaB) in rat renal tissue was assessed by immunohistochemistry. 
      Mouse podocytes cultured in a high concentration of glucose were classified into 
      four groups based on the irbesartan concentrations (0, 25, 50, and 75  masculineg/mL). 
      Expression of ANGPTL2 and phosphorylated IkappaB-alpha was assessed by Western blotting. 
      The mRNA levels of ANGPTL2 and monocyte chemotactic protein 1 (MCP-1) were 
      assessed by real-time polymerase chain reaction. The DKD rats displayed 
      proteinuria, podocyte injury, and increased ANGPTL2 and NF-kappaB expression. All 
      were relieved by irbesartan treatment. In podocytes cultured in elevated glucose, 
      ANGPTL2 and phosphorylated IkappaB-alpha were overexpressed at the protein level, and 
      ANGPTL2 and MCP-1 were highly expressed at the mRNA level. Irbesartan 
      down-regulated ANGPTL2 and phosphorylated IkappaB-alphaexpression at the protein level 
      and inhibited ANGPTL2 and MCP-1 expression at the mRNA level. The ameliorative 
      effects of irbesartan against DKD involves podocyte protection and suppression of 
      ANGPTL2.
FAU - Fang, Ling-Na
AU  - Fang LN
AD  - Department of Endocrinology and Metabolism, Kunshan Hospital Afffiliated to 
      Jiangsu University, Kunshan, Nanjing, 215300, China. fln_d@sina.com.
FAU - Zhong, Shao
AU  - Zhong S
AD  - Department of Endocrinology and Metabolism, Kunshan Hospital Afffiliated to 
      Jiangsu University, Kunshan, Nanjing, 215300, China.
FAU - Huang, Li-Ji
AU  - Huang LJ
AD  - Department of Endocrinology and Metabolism, Jiangsu Hospital of Traditional 
      Chinese Medicine, Nanjing, 210029, China.
FAU - Lu, Bing
AU  - Lu B
AD  - Department of Endocrinology and Metabolism, Kunshan Hospital Afffiliated to 
      Jiangsu University, Kunshan, Nanjing, 215300, China.
FAU - Shen, Li-Wen
AU  - Shen LW
AD  - Department of Endocrinology and Metabolism, Kunshan Hospital Afffiliated to 
      Jiangsu University, Kunshan, Nanjing, 215300, China.
FAU - Tang, Feng-Yan
AU  - Tang FY
AD  - Department of Endocrinology and Metabolism, Kunshan Hospital Afffiliated to 
      Jiangsu University, Kunshan, Nanjing, 215300, China.
FAU - Sun, He-Ping
AU  - Sun HP
AD  - Department of Endocrinology and Metabolism, Kunshan Hospital Afffiliated to 
      Jiangsu University, Kunshan, Nanjing, 215300, China.
FAU - Zhang, Li
AU  - Zhang L
AD  - Department of Endocrinology and Metabolism, Kunshan Hospital Afffiliated to 
      Jiangsu University, Kunshan, Nanjing, 215300, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20210111
PL  - China
TA  - Curr Med Sci
JT  - Current medical science
JID - 101729993
RN  - 0 (Angiopoietin-Like Protein 2)
RN  - 0 (Angiopoietin-like Proteins)
RN  - 0 (Angptl2 protein, rat)
RN  - 0 (NF-kappa B)
RN  - IY9XDZ35W2 (Glucose)
RN  - J0E2756Z7N (Irbesartan)
SB  - IM
MH  - Angiopoietin-Like Protein 2
MH  - Angiopoietin-like Proteins/genetics/*metabolism
MH  - Animals
MH  - Cells, Cultured
MH  - Diabetic Nephropathies/*drug therapy/genetics/metabolism
MH  - Disease Models, Animal
MH  - Drug Administration Schedule
MH  - Glucose/*adverse effects
MH  - Irbesartan/*administration & dosage/pharmacology
MH  - Male
MH  - Mice
MH  - NF-kappa B/metabolism
MH  - Phosphorylation/drug effects
MH  - Podocytes/*cytology/drug effects/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Treatment Outcome
MH  - Up-Regulation/drug effects
OTO - NOTNLM
OT  - angiopoietin-like protein 2 (ANGPTL2)
OT  - diabetes
OT  - inflammation
OT  - kidney
EDAT- 2020/12/03 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/12/02 05:34
PHST- 2020/04/22 00:00 [received]
PHST- 2020/10/02 00:00 [accepted]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PHST- 2020/12/02 05:34 [entrez]
AID - 10.1007/s11596-020-2304-z [pii]
AID - 10.1007/s11596-020-2304-z [doi]
PST - ppublish
SO  - Curr Med Sci. 2020 Dec;40(6):1114-1120. doi: 10.1007/s11596-020-2304-z. Epub 2021 
      Jan 11.